A Phase 3 interventional study of Placebo and IPX066 95 mg LD in Parkinson's Disease, sponsored by Impax Laboratories, LLC. Completed at 60 sites in 7 countries. Open to participants aged 30 Years and older. Per ClinicalTrials.gov, last updated 2019-10-29.
Sponsored by Impax Laboratories, LLC (part of Amneal Pharmaceuticals, Inc.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies in Parkinson Disease by Amneal Pharmaceuticals, Inc. — 1 open to participants now, 1 under way, none of them phase 3. Parkinson Disease · Amneal Pharmaceuticals, Inc..
Among the 14 studies in Parkinson Disease by Amneal Pharmaceuticals, Inc., this one is the 5th largest by enrollment, is one of 2 that started in 2009, is one of 7 in phase 3, and was the 5th registered.
4,578 studies on the registry are indexed under Parkinson Disease; 1,085 are open to participants now.
Browse Parkinson Disease studies →1 of the 14 studies in Parkinson Disease by Amneal Pharmaceuticals, Inc. is open now, in 1 country. Recruiting first, the newest first:
Impax Laboratories, LLC · Sites in United States
Ages 18+
By country, each count listing its studies:
Of the 748 Parkinson Disease studies recruiting now, 311 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.
This study: 30 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 6 · Phase 3 7 · Phase 4 1
First in 2005; this study’s year is marked. 2 started in 2009.
This study's enrollment of 381 is above the median of 40 across 3,357 interventional studies indexed under Parkinson Disease.
Median enrollment 77 across the 14 interventional studies. Of the 13 that completed or were terminated, 9 (69%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Impax Laboratories, LLC, one of the names counted as Amneal Pharmaceuticals, Inc.. Under that name alone:
Impax Laboratories, LLC is the lead sponsor of 20 studies on the registry; 1 is open to participants now.
Of its 8 completed or terminated interventional studies of FDA-regulated products, 2 (25%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 14 studies in Parkinson Disease by Amneal Pharmaceuticals, Inc., from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study examines the efficacy of three doses of IPX066 as compared to placebo in Parkinson's disease.
A randomized, double-blind, placebo-controlled, fixed-dose, parallel-arm study of three doses of IPX066 versus placebo.
Total of 427 subjects were screened and 381 were randomized and received one of the four treatment groups (1) placebo (N=92), (2) IPX066 145 mg LD (N=87) (3) IPX066 245 mg LD (N=104) (4) IPX066 390 mg LD (N=98) three times a day.
Study duration is approximately 30 weeks for each subject including 4 weeks of titration (up to 3 weeks of dose escalation and I week of stabilization for safe escalation to the allocated dose), and 26 weeks of maintenance.
During the titration phase:
The following dose strengths were used to titrate up to the final three strengths that were assigned to the three IPX066 treatment arms.
IPX066 95 mg LD capsule containing 95 mg LD and 23.75 mg CD. IPX066 145 mg LD capsule containing 145 mg LD and 36.25 mg CD. IPX066 195 mg LD capsule containing 195 mg LD and 48.75 mg CD. IPX066 245 mg LD capsule containing 245 mg LD and 61.25 mg CD.
During the maintenance phase:
IPX066 145 mg LD treatment arm received 145 mg LD and 36.25 mg CD. IPX066 245 mg LD treatment arm received 245 mg LD and 61.25 mg CD. IPX066 390 mg LD treatment arm received 390 mg LD and 97.50 mg CD.
Primary efficacy outcome measure was change from baseline in the sum of UPDRS Part II and Part III scores at the end of study or last value reported if subject discontinued prematurely.
Summary of Change From Baseline to End of Study in Mean Parkinson's Disease Questionnaire-39 (PDQ-39) Score.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
One Placebo capsule was given TID for the first 21 days. Two placebo capsules were given TID on days 22 till end of study (week 30).
Drug: Placebo
One IPX066 95 mg LD was given TID on days 1-3. One IPX066 145 mg LD was given TID on days 4-21. One IPX066 145 mg LD and one placebo capsule were given TID on days 22 till end of study (week 30).
Drug: Placebo · Drug: IPX066 95 mg LD · Drug: IPX066 145 mg LD
One IPX066 95 mg LD was given TID on days 1-3. One IPX066 145 mg LD was given TID on days 4-7. One IPX066 195 mg LD was given TID on days 8-14. One IPX066 245 mg LD was given TID on days 15-21. One IPX066 245 mg LD and one placebo capsule were given TID on days 22 till end of study (week 30).
Drug: Placebo · Drug: IPX066 95 mg LD · Drug: IPX066 145 mg LD · Drug: IPX066 195 mg LD · Drug: IPX066 245 mg LD
One IPX066 95 mg LD was given TID on days 1-3. One IPX066 145 mg LD was given TID on days 4-7. One IPX066 195 mg LD was given TID on days 8-14. One IPX066 245 mg LD was given TID on days 15-21. Two IPX066 195 mg LD capsules were given TID on days 22 till end of study (week 30).
Drug: IPX066 95 mg LD · Drug: IPX066 145 mg LD · Drug: IPX066 195 mg LD · Drug: IPX066 245 mg LD
Placebo
IPX066 capsule containing 95 mg LD/23.75 mg CD
Also known as: CD-LD ER 95 mg
IPX066 capsule containing 145 mg LD/36.25 mg CD
Also known as: CD-LD ER 145 mg
IPX066 capsule containing 195 mg LD/48.75 mg CD
Also known as: CD-LD ER 195 mg
IPX066 capsule containing 245 mg LD/61.25 mg CD
Also known as: CD-LD ER 245 mg
Change From Baseline in the Sum of UPDRS Part II + UPDRS Part III at Week 30
Analysis of the Change from Baseline in the sum of the Unified Parkinson's Disease Rating Scale (UPDRS) Part II (Activities of Daily Living) + UPDRS Part III (Motor Examination) at Week 30 (End of Study). Unified Parkinson's Disease Rating Scale (UPDRS) - Four Parts Higher score values represent a worse outcome. Subscales II and III were summed: Part I: Mentation, Behavior and Mood - 4 questions 1-4 Score range: 1-16 Part II: Activities of Daily Living - 13 questions 5-17 Score range: 0-52 Part III: Motor Examination - 19 questions 18-31 and 25 total assessments Score range: 0-100 Part IV: Complications of Therapy (In the past week) - 11 questions Score range: 0-25
Time frame: Week 30
Summary of Change From Baseline to End of Study in Mean Parkinson's Disease Questionnaire-39 (PDQ-39) Score
Change from Baseline in Parkinson's disease Questionnaire 39 (PDQ-39) at Weeks 4, 9, 16, 23 and 30 or early discontinuation was collected. The PDQ-39 is a self-reported questionnaire consisting of 39 questions regarding the subjects mobility and the responses consist of "Never" (better in outcome), (value 0), "Occasionally" (value 1), "Sometimes" (value 2), , "Often" (value 3), and "Always" (value 4), (worse in outcome). The minimum possible score is "0" and the maximum is "156". The outcome measure calculated was the change from baseline to end of study in mean PDQ-39 score. Negative values indicate a better result.
Time frame: Baseline and Week 30 (or End of Study)
First patient enrolled: 4/13/2009 Last patient out 10/05/2010
| Milestone | Placebo | IPX066 145 mg LD | IPX066 245 mg LD | IPX066 390 mg LD |
|---|---|---|---|---|
| Started | 92 | 87 | 104 | 98 |
| Week 4 | 88 | 79 | 94 | 86 |
| Week 9 | 80 | 73 | 88 | 78 |
| Week 16 | 74 | 73 | 87 | 74 |
| Week 23 | 71 | 72 | 85 | 74 |
| Completed | 71 | 72 | 83 | 74 |
| Not completed | 21 | 15 | 21 | 24 |
| Withdrew: Adverse event | 4 | 5 | 15 | 15 |
| Withdrew: Death | 0 | 0 | 1 | 0 |
| Withdrew: Lack of efficacy | 12 | 4 | 0 | 1 |
| Withdrew: Lost to follow-up | 0 | 1 | 1 | 0 |
| Withdrew: Protocol violation | 0 | 1 | 0 | 2 |
| Withdrew: Withdrawal by subject | 4 | 3 | 1 | 3 |
| Withdrew: Noncompliance | 0 | 0 | 1 | 1 |
| Withdrew: Other | 1 | 1 | 2 | 2 |
Analysis of the Change from Baseline in the sum of the Unified Parkinson's Disease Rating Scale (UPDRS) Part II (Activities of Daily Living) + UPDRS Part III (Motor Examination) at Week 30 (End of Study). Unified Parkinson's Disease Rating Scale (UPDRS) - Four Parts Higher score values represent a worse outcome. Subscales II and III were summed: Part I: Mentation, Behavior and Mood - 4 questions 1-4 Score range: 1-16 Part II: Activities of Daily Living - 13 questions 5-17 Score range: 0-52 Part III: Motor Examination - 19 questions 18-31 and 25 total assessments Score range: 0-100 Part IV: Complications of Therapy (In the past week) - 11 questions Score range: 0-25
| units on a scale | Placebo | IPX066 145mg LD | IPX066 245 mg LD | IPX066 390 mg LD |
|---|---|---|---|---|
| Change From Baseline in the Sum of UPDRS Part II + UPDRS Part III at Week 30 | -0.6 ± 10.37 | -11.7 ± 10.97 | -12.9 ± 11.42 | -14.9 ± 11.85 |
Change from Baseline in Parkinson's disease Questionnaire 39 (PDQ-39) at Weeks 4, 9, 16, 23 and 30 or early discontinuation was collected. The PDQ-39 is a self-reported questionnaire consisting of 39 questions regarding the subjects mobility and the responses consist of "Never" (better in outcome), (value 0), "Occasionally" (value 1), "Sometimes" (value 2), , "Often" (value 3), and "Always" (value 4), (worse in outcome). The minimum possible score is "0" and the maximum is "156". The outcome measure calculated was the change from baseline to end of study in mean PDQ-39 score. Negative values indicate a better result.
| score on a scale | IPX066 145 mg LD | IPX066 245 mg LD | IPX066 390 mg LD | Placebo |
|---|---|---|---|---|
| Summary of Change From Baseline to End of Study in Mean Parkinson's Disease Questionnaire-39 (PDQ-39) Score | -4.4 ± 12.18 | -3.8 ± 12.16 | -6.0 ± 12.30 | 0.6 ± 11.10 |
Collected over 1 year, 6 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | — | 3/92 (3.3%) | 26/92 (28.3%) |
| IPX066 145 mg LD | — | 4/87 (4.6%) | 27/87 (31%) |
| IPX066 245 mg LD | — | 5/104 (4.8%) | 47/104 (45.2%) |
| IPX066 390 mg LD | — | 2/98 (2%) | 48/98 (49%) |
| Event | Placebo | IPX066 145 mg LD | IPX066 245 mg LD | IPX066 390 mg LD |
|---|---|---|---|---|
| Acute myocardial infarctionCardiac disorders | 0/92 | 1/87 | 0/104 | 0/98 |
| Coronary artery diseaseCardiac disorders | 0/92 | 1/87 | 0/104 | 0/98 |
| Myocardial infarctionCardiac disorders | 0/92 | 1/87 | 0/104 | 0/98 |
| Escherichia urinary tract infectionInfections and infestations | 0/92 | 1/87 | 0/104 | 0/98 |
| UrosepsisInfections and infestations | 1/92 | 0/87 | 0/104 | 0/98 |
| Cerebrovascular accidentNervous system disorders | 1/92 | 0/87 | 0/104 | 0/98 |
| ProstatectomySurgical and medical procedures | 1/92 | 0/87 | 0/104 | 0/98 |
| Urinary tract infectionInfections and infestations | 0/92 | 0/87 | 0/104 | 1/98 |
| Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders | 0/92 | 0/87 | 0/104 | 1/98 |
| EmphysemaRespiratory, thoracic and mediastinal disorders | 0/92 | 0/87 | 0/104 | 1/98 |
| Event | Placebo | IPX066 145 mg LD | IPX066 245 mg LD | IPX066 390 mg LD |
|---|---|---|---|---|
| NauseaGastrointestinal disorders | 8/92 | 12/87 | 20/104 | 20/98 |
| DizzinessNervous system disorders | 5/92 | 8/87 | 20/104 | 12/98 |
| HeadacheNervous system disorders | 10/92 | 6/87 | 13/104 | 17/98 |
| InsomniaPsychiatric disorders | 3/92 | 2/87 | 9/104 | 6/98 |
| Dry MouthGastrointestinal disorders | 1/92 | 3/87 | 2/104 | 7/98 |
| Abnormal dreamsPsychiatric disorders | 0/92 | 2/87 | 6/104 | 5/98 |
| ConstipationGastrointestinal disorders | 1/92 | 2/87 | 6/104 | 2/98 |
| DepressionPsychiatric disorders | 5/92 | 1/87 | 2/104 | 2/98 |
| VomitingGastrointestinal disorders | 3/92 | 2/87 | 2/104 | 5/98 |
| DyskinesiaNervous system disorders | 0/92 | 2/87 | 4/104 | 5/98 |
Baseline Analysis Population is all treated
| Age, Continuous(years) | Placebo | IPX066 145 mg LD | IPX066 245 mg LD | IPX066 390 mg LD | Total |
|---|---|---|---|---|---|
| Mean | 65.4 ± 9.43 | 63.8 ± 9.81 | 65.2 ± 9.73 | 64.8 ± 9.32 | 64.8 ± 9.55 |
| Sex: Female, Male(Participants) | Placebo | IPX066 145 mg LD | IPX066 245 mg LD | IPX066 390 mg LD | Total |
|---|---|---|---|---|---|
| Female | 40 | 40 | 45 | 44 | 169 |
| Male | 52 | 47 | 59 | 54 | 212 |
| Ethnicity (NIH/OMB)(Participants) | Placebo | IPX066 145 mg LD | IPX066 245 mg LD | IPX066 390 mg LD | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 3 | 5 | 7 | 4 | 19 |
| Not Hispanic or Latino | 87 | 78 | 91 | 89 | 345 |
| Unknown or Not Reported | 2 | 4 | 6 | 5 | 17 |
| Race/Ethnicity, Customized(participants) | Placebo | IPX066 145 mg LD | IPX066 245 mg LD | IPX066 390 mg LD | Total |
|---|---|---|---|---|---|
| Asian | 1 | 0 | 0 | 1 | 2 |
| Black or African American | 0 | 0 | 2 | 0 | 2 |
| White | 90 | 87 | 102 | 96 | 375 |
| Other | 1 | 0 | 0 | 1 | 2 |
| Region of Enrollment(participants) | Placebo | IPX066 145 mg LD | IPX066 245 mg LD | IPX066 390 mg LD | Total |
|---|---|---|---|---|---|
| Canada | 10 | 9 | 9 | 9 | 37 |
| Latvia | 1 | 1 | 0 | 0 | 2 |
| Romania | 13 | 13 | 15 | 14 | 55 |
| United States | 30 | 29 | 37 | 38 | 134 |
| Ukraine | 28 | 29 | 32 | 26 | 115 |
| Lithuania | 7 | 4 | 8 | 8 | 27 |
| Estonia | 3 | 2 | 3 | 3 | 11 |
| Age at Parkinson's disease onset(years) | Placebo | IPX066 145 mg LD | IPX066 245 mg LD | IPX066 390 mg LD | Total |
|---|---|---|---|---|---|
| Mean | 63.7 ± 9.48 | 61.7 ± 10.71 | 63.6 ± 10.43 | 63.0 ± 9.38 | 63.0 ± 10.00 |
| Duration of Parkinson's disease(years) | Placebo | IPX066 145 mg LD | IPX066 245 mg LD | IPX066 390 mg LD | Total |
|---|---|---|---|---|---|
| Mean | 1.8 ± 2.01 | 2.3 ± 3.08 | 1.8 ± 1.85 | 2.0 ± 2.33 | 2.0 ± 2.34 |
| UPDRS Parts II and III Score(units on a scale) | Placebo | IPX066 145 mg LD | IPX066 245 mg LD | IPX066 390 mg LD | Total |
|---|---|---|---|---|---|
| Mean | 36.3 ± 11.89 | 36.1 ± 13.56 | 38.1 ± 15.63 | 36.3 ± 13.04 | 36.7 ± 13.63 |
2 further baseline measures are reported on the registry.
Plan to share: No
The record gives a start of Apr 2009, a primary completion of Oct 2010 and a completion of Nov 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Feb 2016, 5 years 4 months after primary completion. A results delay was requested in Sep 2013.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.